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ABSTRAK 
Metformin meningkatkan sensitivitas insulin tidak hanya tetapi juga fungsi endotel vasladm' dan mengurangi kejadian 
kardiovaskular pada pasien dengan diabetes tipe 2. Terapi oksigen hiperbarik (HBO terapi), 2,4 ATA mengurangi glukosa darah 
secara langsung dengan menggunakan glukosa untuk menghasilkan energi (A TP), memifiki efek pada vasodilatasi dengan 
merangsang Synthase Oxid nitrat (NOS) dan mungkin meningkatkan sensitivitas insulin melalui aktivasi A MPK. Oleh karena itu, 
HBO dianggap sebagai pengobatan adjuvant pada DM tipe 2 di samping metformin. Protein kinase berperan dalam translokasi 
GLUT4 vesikel ke permukaan sel. Dalam studi ini, kami meneliti peran Protein kinase C dalam insulin yang diinduksi GLUT4 dalam 
l71eningkatkan pengurangan glukosa darah. Tujuan dari penelitian ini adalah untuk menemukan manajemen baru dalam optimalisasi 
terapi metforl71in pada pasien dengan diabetes tipe 2, terutama dalam mengurangi glukosa darah, dan meningkatkan konsentrasi 
PKC itu. Hal ini diyakini bahwa progresivity diabetes tergantung pada penampilan dan aktivitas PKC dan peningkatan efek sensitity 
insulin pada GLUT4. Ini adalah studi pra dan pasca klinis percobaan tanpa kontrol. Sepuluh koresponden lald-Iaki chosed secm'a 
acak. Glukosa darah dan konsentrasi PKC digunakan sebagai parameter, diperiksa sebelum, selama dan setelah perawatan 
kombinasi metformin dan HBO terapi diberikan. Glukosa darah berkurang secara signifikan setelah terapi. Titer PKC telah ada 
perubahan signifikan sebelum dan setelah pengobatan. Kesimpulan: Metformin dan terapi OHB mengurangi glukosa darah lapi 
tidak secara signifikanmeningkatkan konsentrasi PKC itu. Cara spesifik me!formin dan efek OHB terapi itu harus dieksplorasi lebih. 
Implikasi klinis dari terapi kombinasi tetap ditentukan. 
ABSTRACT 
Metformin improves not only insulin sensitivity /Jut also vascular endotheliallimctions and reduces cardiovascular events in patients 
with type 2 diabetes. Hyperbaric oxygen therapy (HBO therapy), 2.4 ATA reduces directly blood glucose by using glucose to produce 
energy (ATP), has effect on vasodilatation by stimulating Nitric Oxid Synthase (NOS) and presumably improves Insulin sensitivity 
via AMPK activation. Therefore, HBO is considered as an adjuvant treatment in type 2 DM beside Metformin. Protein kinase plays a 
role in translocation of GLUT4 vesicles to cell sUI/ace. In this study, we investigated the role of Protein Kinase C in insulin-induced 
GLUT4 in improving glucose blood reduction. The aim of this study was to lind a new management in metformin therapy 
optimalisation in patients with type 2 diabetes, especially in redUCing blood glucose, and improving PKC's concentration. It is 
believed that the progresivity of diabetes depends on PKC appearance and activity and the improvement of insulin sensitity effects on 
GLUT4. This was a pre and post experimental clinical study without control. Ten male correspondents were chased randomly. Blood 
glucose and PKC concentrations were used as the parameters, examined before, during and after combined treatment of Metformin 
and HBO therapy were given. Glucose blood reduced significantly after the therapy. PKC's tiler had no significant change before 
and after treatment. Conclusion: Metformin and OHB therapy reduce blood glucose but not significantly increase PKC's 
concentration. The specific ways of Metformin and OHB therapy 's effect should be explored more. The clinical implications of these 
combination therapies remain to be determined. 
Keywords: Met[ormin, OHB therapy, PKC, glucose blood 
Correspondence: Endang lsbandiati , Division of Post Graduated Program of Pharmacology and Therapeutic, 
Department of Pharmacology, Faculty of Medicine, Airlangga Universi ty, Surabaya Indonesia. email: 
endangisbandiati_s@yahoo.com 
INTRODUCTION 
Metformin , the Biguanides derivative, is the first line 
oral anti di abetic (American Diabetes Association 2006; 
PERKENI 2007) used for the treatment of type 2 
diabetes, It is an effective hypoglycemic drug that also 
improves lipid profiles and reduces cardiovascular risk 
The Diabetes Prevention Program has recently shown 
that similar to di et and exercise, Metformin treatment 
reduces the ri sk of developing diabetes in glucose-
intolerant individuals. Whereas most studies have 
shown that the glucose-lowering effects of Metformin 
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are secondary to a decrease in hepatic glucose 
production via its molecular site of action remains 
unclear, AMP-activated protein kinase (AMPK). In 
add ition to its insulin sensitizing effects, Metformin has 
also been shown to have direct vascular effects (Bailey 
2007). 
Protein kinase C (PKC) comprises a multigene family 
that encodes at least 12 distinct isoforms differing in 
catalytic and regulatory properties (Concorelli 2001). 
These PKC isoforms can be divided into the following 
three subgroups based on cofactor requirements: 
conventional PKCs (a, ~, and y), which are dependent 
on Ca2+ and diacylglycerol (DAG) for activity; novel 
PKCs (D, E, Tj , and u), which are not dependent on Ca2+ 
but are activated by DAG; and atypical PKCs (c" A, and 
I) , which are not dependent on Ca2+ and are not 
stimulated by DAG. 
PKC plays a pivotal role in controlling numerous 
cellular functions, including glucose transport. Indeed, 
CUlTent evidence indicates that DAG-dependent PKCs 
may control Insulin dependent glucose transport in 
several different cell types (Dipiro 2009). More recent 
work also indicates that different PKC isoforms have an 
important role in signaling insulin action on glucose 
transport. More recent work also indicates that different 
PKC isoforms have an important role in signaling 
insulin action on glucose transport. It is presumable that 
Metformin improves PKC activity via the action of 
Insulin on glucose transport (Shen et al 2001). In this 
study, our aims is finding the effect of combination 
Metformin and HBO therapy in PKC concentration. 
Despite the long history and success of metformin as a 
treatment for type 2 diabetes , there is a cumulative 
incidence at 5 years study in UK, that the failure of 
Metformin monotherapy is 21% out of 4360 patients 
with type 2 diabetes. Even, to solve the problem of 
Metformin mono therapy failure , patients were given 
combination of with either other oral anti diabetics 
drugs, such as the Thiazolidinediones derivative -
Rosiglitazone; the Sulphonylureas derivative 
Glibenclamide or Insulin analogues. The progress of 
diabetes complication such cardiovascular events were 
sti ll happened. 
In this CUlTent study, Hyperbaric Oxygen (HBO) 
Therapy, used 100 percent oxygen at 2.4 Atmosphere 
Absolute (ATA), is considered as an adjuvant treatment 
in patients with type 2 diabetes and Metformin 
mono therapy failure, especially in improving PKC 
activity. 
MATERIALS AND METHODS 
The one group pre - post without control design. A total 
of 10 indonesian men with type 2 diabetes were selected 
among 20 subjects recruited in the context of a study on 
Metformin monotherapy failure at the Department of 
Internal Medicine, Naval Hospital Dr.Ramelan 
Surabaya to represent as subjects in this study. The age 
ranged from 50 to 65 years and type 2 diabetes on the 
basis of more than 7% in HbAl according to American 
Diabetes Association criteria. All subjects fulfilled the 
following inclusion criteria: 1) absence of any acute or 
chronic inflammatory diseases as determined by a 
leukocyte count or clinical signs of infection, 2) no 
medical history of hypertension (i.e., systolic blood 
pressure was less than 140 mmHg and diastolic blood 
pressure was less than 85 mmHg, 3) no clinical 
evidence of either cardiovascular or peripheral artery 
disease, 4) no thyroid dysflmction, 5) no contra 
indications for both Metfonnin or HBO therapy, 6) do 
diet for diabetes, 7) no Insulin therapy and 8) no anti 
scavenger (i.e., Ca2+ supplement, Vitamin E) within 
last 6 months. The study was approved by the ethics 
committee of the Medical Faculty University of 
Airlangga. All subjects gave written informed consent 
before taking part in the study. 
Ten subjects were given Metformin 500 mg 4 times a 
day and HBO therapy 2.4 ATA 10 sessions within 10 
days with 2 days without HBO therapy. One HBO 
session took around 2 hours therapy with 3 activities , 1) 
10 minutes adaptation for the change of the atmosphere 
pressure at the sea ,level, 2) breath with 100 percent 
Oxygen, 3 times 30 minutes with 5 minutes interval, 3) 
10 minutes adaptation for back to the normal 
atmosphere pressure. All based line blood sample were 
collected three times within the treatment of HBO 
periods for measuring blood glucose, PKC 
concentration and hepar - renal function. First 
measurement was taken before the subj ects entered 
HBO chamber (pre test) . Second measurement was 
taken after the HBO therapy day 5th (durantee test) and 
the last measurement was taken after the subjects come 
out from HBO chamber day 10th (post test). 
Assays, measures of blood glucose and liver - kidneys 
function. Samples were using serum, that took from 30 
minutes clotting whole blood then centrifuged for IS 
minutes at approximately 1000 x g, then homogenized 
and measured with "fortex mixer" equipments. PKC 
ELISA development and measurement of PKC serum 
concentrations. 
The gene-encoding human PKC was amplified from the 
human pPKC cDNA library by PCR, standard E. coli-
expressed PKC was used as an immunogen for 
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generating human PKC - specific monoclonal and 
polyclonal Abs. For making recombinant PKC proteins 
in HEK293 cells and E. coli, the portion of the gene 
encompassing presumed mature polypeptides, Leu21 
through Lys414, was amplified and digested with 
appropriate restriction enzymes and then cloned into 
pPKC (USCN Life Science Inc.,Wuhan, China). 
Standards and samples are pipetted into the wells and 
any pPKC present is bound by the immobilized 
antibody. An enzyme-linked polyclonal antibody 
specific for p-PKC is added to the wells. Following a 
wash to remove any unbound antibody-enzyme reagent, 
a substrate solution is added to the wells and color 
develops in proportion to the amount of p-PKC bound 
in the initial step. The color development is stopped and 
the intensity of the color is measured. 
Data are shown as means SE, unless stated otherwise. 
Before statistical analysis , normally distributed 
parameters were logarithmically approximate a normal 
distribution (Kolmogorov-Smirnov test). The following 
statistical tests were used: paired Student's t test or 
paired samples test. Statistical analysis was performed 
using SPSS version 14.0 (Chicago, IL). P values _0.05 
were considered to be statistically significant. 
RESULTS 
Development and validation of PKC ELISA. The 
CUlTent ELISA system was made possible by a human 
PKC - specific monoclonal antibody. We were able to 
observe a certain range of semm PKC levels from all 
the sera we tested. PKC semm concentrations in 
response to combination Metformin and 10 sessions of 
HBO therapy. A total of 10 Indonesian men and women 
completed a combination Metformin and HBO therapy 
program. The treatment effect was confirmed by a 
significant improvement in reducing blood glucose in 
all subjects (tab le and figurel.l), on the other hand, the 
treatment was not significant improvement in PKC 
concentration (Table and Figure 1). 
Table 1. Paired t-Test for Fasting Blood Glucose (FBG) 
Pair 1 
Pair 2 
Pair 3 
Paired I-Test 
FBG_l - FBG_Il (pre - durantee HBO) 
FBG_II - FBG_III (durantee - post HBO) 
FBG_l - FBG_11I (pre - post HBO) 
Sig. = signifi cant < 0,05; Resource: SPSS version 14.0 
Sig. Mean 
.000 55.2 
.0 11 26.7 
.000 81.5 
FOO 
2:iIO 
~ 
160 
tOO 
50 
0 
• 
Fig. l. The chart of reducing (fasting) blood glucose . 
Series 1 = 1 st measurement; Series 2 = 2nd 
measurement; Series 3 = 3rd measurement 
I 
Table 2: Paired t-Test for PKC concentration 
Paired t-Test Sig. 
Pair 1 PKC_' - PKC _" (pre - durantee HBO) .598 
Pair 2 PKC _II - PKC _III (durantee - post HBO) .235 
Pair 3 PKC' - PK C "' (pre - post HBO) .234 
Sig. - significant < 0,05 ; Resource: SPSS version 14.0 
PKe 
lO T··········································· · ······· ••••... ..•..•..••.•. .. .. .. ......•..... .. ....... ...•..... . ... . ....••....... 
o 
Mean 
-0.185 
1.131 
.946 
1011 
" II I 
Fig. 2 : The chart of improvement PKC concentration. 1 
= 1st measurement; Il= 2nd measurement; 
Series III = 3rd measurement 
Hepar and Renal functions . Hepar function was 
evaluated by SGOT and SGPT during combination 
Metformin and HBO therapy were given. It needed to 
evaluate because of Metfonnin's mainly work was in 
hepar. Metfonnin therapy was considered to stop if 
hepar function increased (Goodman and Gilman ' s 
2006). Result of hepar function was no significant 
raised (Table and Figure 3). 
, e. 
!nd 
.1 5 
.1 31 
.9-16 
n. l 
ent; 
I\'as 
tion 
i to 
' m 
) if 
ill'S 
:ant 
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Table 3 : Paired Samples Test for SGOT and SGPT 
Pa ired Samples Test Sig. 
Pair I SGOT _ I - SGOT _" (pre - durantee HBO) .061 
Pair2 SGOT _" - SGOT _111 (durantee - post HBO) .015 
Pair 3 SGOT -' - SGOT _ Ill (pre - post HBO) .893 
Pair 4 SGPT_I - SGPT_II(pre - durantee HBO) .541 
Pair 5 SGPT _" - SGPT _III (durantee - post HBOl .560 
Pair 6 SGPT 1 - SGPT III (pre - post HBO) .443 
Sig. = si gnificant < 0,05 ; Resource: SPSS version 14.0 
Mean 
1.40 
1.20 
.10 
.30 
.30 
.60 
Renal function was evaluated by BUN and Creatinine 
Serum during combination Metformin and HBO therapy 
were given. It needed to evaluate because of 
Metformin's mainly excretion was in renal. Metformin 
therapy was considered to stop if there is impaired in 
renal function (Goodman and Gilman ' s 2006). Result of 
SGOT 
3J + ... 00 .... ..... .. 0 . . ....................... ... .............................. . ... . 
15 
10 
; 
., 
iSeriesl 
m Seriest 
W$eri es3 
B 
renal function was no significant raised (Table and 
Figure 4). 
Table 4: Paired t-Test for BUN dan Creatinine Serum 
(SK) 
Paired t-Test Sig. Mean 
Pair 1 BUN_T - BUN_ " (pre - durantee 
.771 .77 1 HBO) 
Pair 2 BUN_ II - BUN_Trr (duran(ee - post 
.479 .479 HBO) 
Pair 3 BUN_T - BUN_ III (pre - post HBO) .364 .364 
Pair 4 SK_ T - SK_ TI (pre - durantee HBO) 1.00 1.00 
Pair 5 SK_Il - SK_ lll (durantee - post HBO) 1.00 1.00 
Pair 6 SK 1- SK III (Ere - EOs! HBO) 1.00 1.00 
Sig. = significant < 0,05 ; Resource: SPSS version 14.0 
SGPT 
30 .+ ......................................................................................................... " ...... .. 
m Seriesl 
• Se ri e~.2 
Ie 
-' 
10 
Fig. 3 : Chart (A) result ofSGOT evaluation; (B) result ofSGPT evaluation. series 1 = 1st measurement ofSGOT and 
SGPT, series 2 = 2nd measurement ofSGOT and SGPT, series 3 = 3rd measurement ofSGOT and SGPT 
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A BUN CREA IDI\E SERHI 
2D.O 
14 
15.Q ,., _ .L 
14.0 ~ Se rie$l 10 
12.0 
100 mS" ri€12 0.8 
8.0 'I S"riel3 0.6 
6.0 
04 
U 
00 
Fig. 4: Chart (A) result of BUN evaluation; (B) result of SK evaluatiob. series 1 = 1 st measurement of BUN and SK. 
series 2 = 2nd measurement of BUN and SK, series 3 = 3rd measurement of B UN and SK 
DISCUSSION 
Previous studies in other laboratories have shown that 
medium-level improvement of classic PKCs, including 
PKC-a and -~ , may improve insulin responses by 
inducing early steps in the insulin signal transduction 
system. insulin receptor autophosphorylation, 
phosphorylation of IRS-l and IRS-2, and 
phosphatidylinositol (PI) 3-kinase activation occur 
normally so that blood glucose reached nearly 
"normoglycaemia". In our study, PKC concentration 
was not significant increased after giving combination 
of Metfonnin and HBO therapy but the subjects ' blood 
glucose were nearly "nOImo-glycemia". It presumable 
Metformin and HBO therapy had synergism effect in 
reducing hyperglycemia condition. HBO -therapy has 
effect as same as exercise so that able to activate 
AMPK, thus glucose was able to use as A TP resource. 
However, specific mechanism of action combination 
Metfomin and HBO therapy remains to be determined. 
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